VitroLabs, Inc. is a San Jose, California-based startup specializing in 3D tissue engineering through innovative stem cell technologies. Founded in 2016, the company focuses on developing scalable platforms for creating authentic biomaterials, allowing for the production of luxury lab-grown leather and fur without the need to raise or slaughter animals. By leveraging advancements in stem cell research and biomaterials, VitroLabs provides sustainable alternatives for fashion brands and interior product manufacturers, promoting ethical practices in the industry.
Leaft Foods is a producer of plant-based protein focused on promoting both environmental and human health. The company utilizes abundant sources of natural protein, particularly extracting protein from lush green leaves through a paddock-to-production process. This approach allows Leaft Foods to provide food companies with sustainable and nutritious leaf protein ingredients, facilitating the creation of edible food products that align with growing consumer demand for plant-based options. Operating within New Zealand's pasture-based agricultural economy, Leaft Foods demonstrates the viability of its innovative practices in both nutrition and sustainability.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies for age-related diseases by targeting senescent cells. Incorporated in 2018, the company utilizes its ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates that selectively eliminate senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations resulting from cellular stress and damage. By promoting selective apoptosis in aged or pathological tissues, Rubedo aims to regenerate tissues, improve the function of healthy cells, and ultimately extend the health span of patients. The company is dedicated to addressing the challenges posed by age-related conditions through innovative therapeutic solutions.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Gen1E Lifesciences is a developer of a platform designed to accelerate cures for inflammatory and age-related diseases.The company's services include a pipeline of preclinical stage products that includes a P38 kinase inhibitor for the treatment of various inflammatory diseases, enabling medical researchers to optimize existing regulatory incentives, reduce the required R&D time and cost, truncate the time to exit and improve the success rate in receiving FDA approval and commercial success.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.
BioAge Labs, Inc. is a biotechnology company focused on developing therapies for aging and age-related diseases. The company utilizes a proprietary systems biology and artificial intelligence platform to identify crucial drug targets that influence aging, leveraging extensive datasets to uncover the molecular drivers behind age-related conditions. BioAge Labs offers several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor aimed at treating multiple diseases of aging by activating HIF-1 target genes linked to various biological processes such as tissue regeneration and vascular remodeling. Another candidate, BGE-175, is an orally administered inhibitor that targets the prostaglandin D2 DP1 signaling pathway, which is associated with increased mortality risk and susceptibility to infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to advancing the understanding and treatment of aging-related health issues.
Loop Genomics is a platform technology for long-read DNA sequencing. Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines. Loop Genomics long-read DNA sequencing technology provides phased sequencing solutions across a diverse repertoire of research and clinical applications. Sequencing of partial rRNA gene sequences results in reduced phylogenetic resolution. Full-length, high-throughput, phased sequencing that covers all 16S variable regions is becoming the gold standard for profiling the microbiome. Achieve the highest resolution microbial community profiling with long-read, next-generation sequencing of the microbiome. Characterizing polymorphisms in HLA genes inside and outside of the protein-coding regions is important for organ transplantation compatibility testing and for strengthening causality association studies. The length of homologous sequences between HLA alleles extends beyond the capabilities of short-read sequencing platforms, resulting in diploid ambiguities and a reliance on imputation. Sequence full-length HLA DNA and/or RNA with phased, high throughput, long-read sequencing that resolves allelic discrimination and diploid ambiguity. Viral genetic variability is a major determinant of viral drug resistance and viral vaccine efficacy. Accurately mapping viral genetic variability is a critical step in choosing the optimal course of therapy and developing efficacious vaccines. Key mutations are typically located throughout long stretches of viral genomes, making the retrieval of critical phased data challenging using short-read sequencing technology. Use phased, high-throughput DNA sequencing technology to map key mutations at the quasi-species level and generate a complete phased map of viral populations.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Ontera develops a hand-held point of use diagnostic platform that examines DNA and RNA, and analytes (proteins, viruses, antibodies, etc) from any life form. Use in human and animal diagnostics, agriculture, food safety testing, environmental monitoring, and more. Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.
GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.